BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

925 related articles for article (PubMed ID: 29936771)

  • 1. [Prognostic value of pretreatment neutrophil-to-lymphocyte ratio (NLR) in locally advanced non-small cell lung cancer patients treated with thoracic radiation].
    Dong X; Zhou ZM; Bi N; Wang JB; Ran JT; Hui ZG; Liang J; Feng QF; Chen DF; Xiao ZF; Lyu JM; Wang XZ; Wang X; Zhang T; Deng L; Wang WQ; Wang LH
    Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):446-451. PubMed ID: 29936771
    [No Abstract]   [Full Text] [Related]  

  • 2. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy.
    Berardi R; Rinaldi S; Santoni M; Newsom-Davis T; Tiberi M; Morgese F; Caramanti M; Savini A; Ferrini C; Torniai M; Fiordoliva I; Bower M; Cascinu S
    Oncotarget; 2016 May; 7(18):26916-24. PubMed ID: 27029035
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
    Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
    Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of neutrophil-to-lymphocyte ratio change in patients with locally advanced non-small cell lung cancer treated with thoracic radiotherapy.
    Yin X; Chen H; Sun Y; Xiao L; Lu H; Guo W; Yang H; Zhou J; Fan K; Liang W
    Sci Rep; 2024 May; 14(1):11984. PubMed ID: 38796631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The prognostic role of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with stage III non-small cell lung cancer treated with concurrent chemoradiotherapy.
    Yılmaz U; Ozdemir O; Batum O; Ermin S
    Indian J Cancer; 2018; 55(3):276-281. PubMed ID: 30693894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic value of prognostic nutritional index (PNI) and neutrophil to lymphocyte ratio (NLR) for advanced non-small cell lung cancer treated with platinum-based chemotherapeutics.
    Wang J; Liu Y; Mi X; Shao M; Liu L
    Ann Palliat Med; 2020 May; 9(3):967-978. PubMed ID: 32389020
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil:lymphocyte ratio as a simple and novel biomarker for prediction of locoregional recurrence after chemoradiotherapy for squamous cell carcinoma of the anus.
    Toh E; Wilson J; Sebag-Montefiore D; Botterill I
    Colorectal Dis; 2014 Mar; 16(3):O90-7. PubMed ID: 24148256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combination of plasma fibrinogen and neutrophil lymphocyte ratio (F-NLR) is a predictive factor in patients with resectable non small cell lung cancer.
    Wang H; Zhao J; Zhang M; Han L; Wang M; Xingde L
    J Cell Physiol; 2018 May; 233(5):4216-4224. PubMed ID: 29057536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of the SUVmax Measured From FDG PET and Neutrophil-to-lymphocyte Ratio Improves Prediction of Clinical Outcomes in Patients With Locally Advanced Non-small-cell Lung Cancer.
    Guo D; Jin F; Jing W; Li M; Chen D; Zou B; Jiang G; Fu L; Zhu H; Kong L; Wu J; Yu J; Yue J
    Clin Lung Cancer; 2019 Nov; 20(6):412-419. PubMed ID: 31300364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The post-treatment neutrophil-to-lymphocyte ratio and changes in this ratio predict survival after treatment of stage III non-small-cell lung cancer with conventionally fractionated radiotherapy.
    Wang D; Guo D; Li A; Wang P; Teng F; Yu J
    Future Oncol; 2020 Mar; 16(9):439-449. PubMed ID: 32141321
    [No Abstract]   [Full Text] [Related]  

  • 15. [Impact of neutrophil-to-lymphocyte ratio on the prognosis of patients with locally advanced colorectal cancer].
    Jiang H; Wang H; Li A; Tang E; Chen Y; Wang A; Deng X; Lin M
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 May; 20(5):550-554. PubMed ID: 28534334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Baseline neutrophil-lymphocyte ratio (≥2.8) as a prognostic factor for patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation.
    Shen L; Zhang H; Liang L; Li G; Fan M; Wu Y; Zhu J; Zhang Z
    Radiat Oncol; 2014 Dec; 9():295. PubMed ID: 25518933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer.
    Bagley SJ; Kothari S; Aggarwal C; Bauml JM; Alley EW; Evans TL; Kosteva JA; Ciunci CA; Gabriel PE; Thompson JC; Stonehouse-Lee S; Sherry VE; Gilbert E; Eaby-Sandy B; Mutale F; DiLullo G; Cohen RB; Vachani A; Langer CJ
    Lung Cancer; 2017 Apr; 106():1-7. PubMed ID: 28285682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neutrophil-to-lymphocyte ratio predicts the survival in patients with post-operative recurrence of non-small cell lung cancer].
    Wang X; Li K
    Zhonghua Zhong Liu Za Zhi; 2014 Apr; 36(4):298-302. PubMed ID: 24989918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-treatment neutrophil-to-lymphocyte ratio predicts prognosis in patients with locoregionally advanced laryngeal carcinoma treated with chemoradiotherapy.
    Zeng YC; Chi F; Xing R; Xue M; Wu LN; Tang MY; Wu R
    Jpn J Clin Oncol; 2016 Feb; 46(2):126-31. PubMed ID: 26611205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.